AOBiome
focuses on developing skin care products that restore ammonia-oxidizing bacteria... Read moreAOBiome
focuses on developing skin care products that restore ammonia-oxidizing bacteria... Read more
News
Oct 09, 2024
EIN Presswire
Press Release: AOBiome : USPTO Grants AOBiome Therapeutics Composition of Matter Patent for its Clinical Candidate B244
Jan 08, 2024
Pharmaceutical Business Review
AOBiome: AOB Pharma, Maruho partner to develop B244 for inflammatory ailments
May 16, 2023
FinanzNachrichten
AOBiome: Biorasi, LLC: Biorasi Featured in AOBiome B244 Clinical Study Report in The Lancet's eClinicalMedicine
Apr 06, 2023
StreetInsider
Press Release: AOBiome : AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244
Nov 16, 2021
Picante Today
AOBiome: AOBiome Reaches Key Enrollment Goal For Largest Clinical Trial Ever With A Topical Biotherapeutic
Aug 17, 2021
Markets Insider
AOBiome: New 30 Patient Study Of AOBiome's New Shelf-Stable Formulation Of Its Ammonia Oxidizing Bacteria (AOB) Shows Reduction Of Itch Levels In Both Pediatric And Adult Subjects Who Suffer From Eczema.
Jul 15, 2021
Markets Insider
AOBiome: Nature Scientific Reports has published a peer reviewed paper showing important immune response benefits associated with AOBiome's B244 Ammonia Oxidizing Bacteria drug therapy
Jun 30, 2020
FinanzNachrichten
AOBiome: AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults
Mar 06, 2019
PR Newswire
Press Release: AOBiome : AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis
Jan 02, 2019
PR Newswire
Press Release: AOBiome : AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema
AOBiome Competitors
1
2
3
4
5
6
7
8
9
10